These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38238963)

  • 1. Assessment of the upper limb function, strength, and mobility in treatment-naive children with spinal muscular atrophy Types 2 and 3.
    Milev E; Selby V; Wolfe A; Rohwer A; Tillmann R; Ramsey D; Iodice M; Hogrel JY; Baranello G; Scoto M; Muntoni F
    Muscle Nerve; 2024 Mar; 69(3):340-348. PubMed ID: 38238963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes in respiratory and upper limb function in a pediatric type III spinal muscular atrophy cohort after loss of ambulation.
    Wolfe A; Scoto M; Milev E; Muni Lofra R; Abbott L; Wake R; Rohwer A; Main M; Baranello G; Mayhew A; Marini-Bettolo C; Muntoni F
    Muscle Nerve; 2021 Nov; 64(5):545-551. PubMed ID: 34432301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'Reading the palm' - A pilot study of grip and finger flexion strength as an outcome measure in 5q spinal muscular atrophy.
    Weber C; Müller A; Freigang M; von der Hagen M; Günther R
    Brain Dev; 2024 May; 46(5):189-198. PubMed ID: 38331667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Wenzel F; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Walter MC; Bertsche A; Vill K; Baumann M; Baumgartner M; Cordts I; Eisenkölbl A; Flotats-Bastardas M; Friese J; Günther R; Hahn A; Horber V; Husain RA; Illsinger S; Jahnel J; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schwerin-Nagel A; Reihle C; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Trollmann R; Weiler M; Weiß C; Wiegand G; Wilichowski E; Ziegler A; Lochmüller H; Kirschner J;
    Orphanet J Rare Dis; 2022 Oct; 17(1):384. PubMed ID: 36274155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The applicability of four clinical methods to evaluate arm and hand function in all stages of spinal muscular atrophy type II.
    Werlauff U; Fynbo Steffensen B
    Disabil Rehabil; 2014; 36(25):2120-6. PubMed ID: 24579651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes.
    Coratti G; Carmela Pera M; Montes J; Scoto M; Pasternak A; Bovis F; Sframeli M; D'Amico A; Pane M; Albamonte E; Antonaci L; Lia Frongia A; Mizzoni I; Sansone VA; Russo M; Bruno C; Baranello G; Messina S; Dunaway Young S; Glanzman AM; Duong T; de Sanctis R; Stacy Mazzone E; Milev E; Rohwer A; Civitello M; Darras BT; Bertini E; Day J; Muntoni F; De Vivo DC; Finkel RS; Mercuri E
    Neuromuscul Disord; 2022 Jan; 32(1):36-42. PubMed ID: 34980538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.
    Wolfe A; Stimpson G; Ramsey D; Coratti G; Dunaway Young S; Mayhew A; Pane M; Rohwer A; Muni Lofra R; Duong T; O'Reilly E; Milev E; Civitello M; Sansone VA; D'Amico A; Bertini E; Messina S; Bruno C; Albamonte E; Mazzone E; Main M; Montes J; Glanzman AM; Zolkipli-Cunningham Z; Pasternak A; Marini-Bettolo C; Day JW; Darras BT; De Vivo DC; Baranello G; Scoto M; Finkel RS; Mercuri E; Muntoni F;
    J Neuromuscul Dis; 2024; 11(3):665-677. PubMed ID: 38427497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different trajectories in upper limb and gross motor function in spinal muscular atrophy.
    Coratti G; Pera MC; Montes J; Pasternak A; Scoto M; Baranello G; Messina S; Dunaway Young S; Glanzman AM; Duong T; De Sanctis R; Mazzone ES; Milev E; Rohwer A; Civitello M; Pane M; Antonaci L; Frongia AL; Sframeli M; Vita GL; DʼAmico A; Mizzoni I; Albamonte E; Darras BT; Bertini E; Sansone VA; Bovis F; Day J; Bruno C; Muntoni F; De Vivo DC; Finkel R; Mercuri E
    Muscle Nerve; 2021 Nov; 64(5):552-559. PubMed ID: 34327716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Dec; 29(12):3666-3675. PubMed ID: 36047967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revised upper limb module for spinal muscular atrophy: Development of a new module.
    Mazzone ES; Mayhew A; Montes J; Ramsey D; Fanelli L; Young SD; Salazar R; De Sanctis R; Pasternak A; Glanzman A; Coratti G; Civitello M; Forcina N; Gee R; Duong T; Pane M; Scoto M; Pera MC; Messina S; Tennekoon G; Day JW; Darras BT; De Vivo DC; Finkel R; Muntoni F; Mercuri E
    Muscle Nerve; 2017 Jun; 55(6):869-874. PubMed ID: 27701745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial.
    Seferian AM; Moraux A; Canal A; Decostre V; Diebate O; Le Moing AG; Gidaro T; Deconinck N; Van Parys F; Vereecke W; Wittevrongel S; Annoussamy M; Mayer M; Maincent K; Cuisset JM; Tiffreau V; Denis S; Jousten V; Quijano-Roy S; Voit T; Hogrel JY; Servais L
    PLoS One; 2015; 10(4):e0121799. PubMed ID: 25861036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revised upper limb module for spinal muscular atrophy: 12 month changes.
    Pera MC; Coratti G; Mazzone ES; Montes J; Scoto M; De Sanctis R; Main M; Mayhew A; Muni Lofra R; Dunaway Young S; Glanzman AM; Duong T; Pasternak A; Ramsey D; Darras B; Day JW; Finkel RS; De Vivo DC; Sormani MP; Bovis F; Straub V; Muntoni F; Pane M; Mercuri E;
    Muscle Nerve; 2019 Apr; 59(4):426-430. PubMed ID: 30677148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risdiplam for the treatment of adults with spinal muscular atrophy: Experience of the Northern Ireland neuromuscular service.
    McCluskey G; Lamb S; Mason S; NicFhirleinn G; Douglas I; Tirupathi S; Morrison KE; McConville J
    Muscle Nerve; 2023 Feb; 67(2):157-161. PubMed ID: 36382958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship Between Hand Strength and Function in Duchenne Muscular Dystrophy and Spinal Muscular Atrophy: Implications for Clinical Trials.
    Decostre V; De Antonio M; Servais L; Hogrel JY
    J Neuromuscul Dis; 2024; 11(4):777-790. PubMed ID: 38788084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures.
    Kessler T; Sam G; Wick W; Weiler M
    Eur J Neurol; 2024 Jan; 31(1):e16099. PubMed ID: 37823715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen in Adults with 5q Spinal Muscular Atrophy: a Systematic Review and Meta-analysis.
    Gavriilaki M; Moschou M; Papaliagkas V; Notas K; Chatzikyriakou E; Papagiannopoulos S; Arnaoutoglou M; Kimiskidis VK
    Neurotherapeutics; 2022 Mar; 19(2):464-475. PubMed ID: 35178673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.